Long-Term Quality of Life Following Transthoracic and Transhiatal Esophagectomy for Esophageal Cancer.
Esophageal neoplasms
Esophagectomy
Quality of life
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
24
04
2020
accepted:
24
08
2020
pubmed:
11
9
2020
medline:
6
8
2021
entrez:
10
9
2020
Statut:
ppublish
Résumé
The impact of transthoracic (TTE) and transhiatal esophagectomy (THE) on long-term health-related quality of life (HR-QoL) in patients with distal esophageal or gastro-esophageal junction (GEJ) cancer has been studied with variable results. This study investigates long-term HR-QoL in patients having undergone TTE or THE. Disease-free patients after TTE or THE for distal esophageal or GEJ cancer with a follow-up > 2 years were included. Patients who visited the outpatient clinic of a tertiary referral center between 2014 and 2018 were asked to complete EORTC-QLQ-C30 and EORTC-QLQ-OG25 questionnaires. Uni- and multivariable linear regression analysis of HR-QoL was performed in all patients and in subgroups of minimally invasive esophagectomy and neoadjuvant therapy. A total of 132 patients after TTE and 56 after THE were included. When compared with the general population, all patients reported worse HR-QoL in 'role functioning' and 'social functioning' and in a range of disease- and/or treatment-specific symptoms. The only significant difference between TTE and THE was a better HR-QoL score for "hair loss" following TTE (ß = 29.4,95%CI = -49.108 - -9.671, p = 0.016). Subgroup analysis of minimally invasively operated patients showed better scores in "physical functioning" following TTE (ß = 13.8,95%CI = 2.755-24.933, p = 0.030). No significant differences in HR-QoL were found between TTE and THE after neoadjuvant therapy. Long-term HR-QoL is largely comparable in disease-free patients following TTE or THE for distal esophageal or GEJ cancer. If there were differences between the surgical groups, they were in favor of TTE. These findings may aid in preoperative counseling of patients with esophageal or GEJ cancer.
Sections du résumé
BACKGROUND
The impact of transthoracic (TTE) and transhiatal esophagectomy (THE) on long-term health-related quality of life (HR-QoL) in patients with distal esophageal or gastro-esophageal junction (GEJ) cancer has been studied with variable results. This study investigates long-term HR-QoL in patients having undergone TTE or THE.
METHODS
Disease-free patients after TTE or THE for distal esophageal or GEJ cancer with a follow-up > 2 years were included. Patients who visited the outpatient clinic of a tertiary referral center between 2014 and 2018 were asked to complete EORTC-QLQ-C30 and EORTC-QLQ-OG25 questionnaires. Uni- and multivariable linear regression analysis of HR-QoL was performed in all patients and in subgroups of minimally invasive esophagectomy and neoadjuvant therapy.
RESULTS
A total of 132 patients after TTE and 56 after THE were included. When compared with the general population, all patients reported worse HR-QoL in 'role functioning' and 'social functioning' and in a range of disease- and/or treatment-specific symptoms. The only significant difference between TTE and THE was a better HR-QoL score for "hair loss" following TTE (ß = 29.4,95%CI = -49.108 - -9.671, p = 0.016). Subgroup analysis of minimally invasively operated patients showed better scores in "physical functioning" following TTE (ß = 13.8,95%CI = 2.755-24.933, p = 0.030). No significant differences in HR-QoL were found between TTE and THE after neoadjuvant therapy.
CONCLUSION
Long-term HR-QoL is largely comparable in disease-free patients following TTE or THE for distal esophageal or GEJ cancer. If there were differences between the surgical groups, they were in favor of TTE. These findings may aid in preoperative counseling of patients with esophageal or GEJ cancer.
Identifiants
pubmed: 32909195
doi: 10.1007/s11605-020-04783-4
pii: 10.1007/s11605-020-04783-4
pmc: PMC8275507
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1657-1666Informations de copyright
© 2020. The Author(s).
Références
Eur J Cancer. 2007 Sep;43(14):2066-73
pubmed: 17702567
Cancer. 2000 Apr 15;88(8):1781-7
pubmed: 10760752
Br J Surg. 2018 Feb;105(3):230-236
pubmed: 29405281
Ann Oncol. 2018 Feb 1;29(2):445-451
pubmed: 29126244
J Clin Oncol. 2004 Oct 15;22(20):4202-8
pubmed: 15483031
Surg Endosc. 2012 Jan;26(1):168-76
pubmed: 21853394
Cancer. 2007 Aug 1;110(3):686-93
pubmed: 17582628
World J Surg. 2015 Aug;39(8):1986-93
pubmed: 26037024
J Clin Oncol. 2018 Jan 20;36(3):268-275
pubmed: 29161204
Ann Surg. 2015 Aug;262(2):286-94
pubmed: 25607756
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
Eur J Cancer. 2012 Jul;48(11):1602-7
pubmed: 22119353
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
Cancers (Basel). 2019 Feb 05;11(2):
pubmed: 30764578
Dis Esophagus. 2020 Nov 18;33(11):
pubmed: 32444879
Ann Surg. 2020 Jun;271(6):1095-1101
pubmed: 30676381
Dis Esophagus. 2015 Oct;28(7):652-9
pubmed: 25059631
Acta Oncol. 2018 Feb;57(2):195-202
pubmed: 28723307
Cancer. 2005 May 1;103(9):1791-9
pubmed: 15779022
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Ann Surg Oncol. 2019 Dec;26(13):4765-4772
pubmed: 31620943
J Thorac Cardiovasc Surg. 2009 Jan;137(1):36-42
pubmed: 19154899
Ann Thorac Surg. 2001 Jul;72(1):306-13
pubmed: 11465217
Br J Surg. 2006 Sep;93(9):1084-90
pubmed: 16779881
Ann Surg. 2007 Dec;246(6):992-1000; discussion 1000-1
pubmed: 18043101
Ann Surg Oncol. 2013 May;20(5):1639-45
pubmed: 23271489
Br J Surg. 2017 Aug;104(9):1131-1140
pubmed: 28632926
Ann Surg. 2017 Aug;266(2):232-236
pubmed: 28187044
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005